Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Neoplasms
  • Pyrazoles
  • Pyrimidines
  • Receptor Protein-Tyrosine Kinases

abstract

  • Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913 , NCT02637687 , and NCT02576431 .).

authors

publication date

  • February 22, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1714448

PubMed ID

  • 29466156

Additional Document Info

start page

  • 731

end page

  • 739

volume

  • 378

number

  • 8